



THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A compound of the formula (I)



wherein:

5 R<sub>2</sub> is selected from hydrogen, hydroxyl, O-alkyl, O-alkenyl, O-benzoyl, O-alkanoyl, O-alkenoyl, O-aryl, O-heterocyclic, O-heteroaryl or




10 wherein R<sub>5</sub> and R<sub>7</sub> are independently selected from hydrogen, alkanoyl, alkenoyl, benzoyl or benzoyl alkyl substituted alkanoyl;

R<sub>3</sub> is selected from hydroxyl, O-alkanoyl, O-alkenoyl, O-benzoyl, O-alkyl, O-alkenyl, O-aryl, O-heterocyclic or O-heteroaryl;

15 R<sub>4</sub> is selected from -CH<sub>2</sub>OH, COOH, CH<sub>2</sub>OCOCH<sub>3</sub>, COO alkyl, COO aryl, CH<sub>2</sub>COO alkyl, COO-heterocyclic, COO-heteroaryl, CH<sub>2</sub>-O aryl, CH<sub>2</sub>O heterocyclic or CH<sub>2</sub>O heteroaryl;


R<sub>6</sub> is selected from hydrogen or



$R_1$  is selected from hydrogen or alkyl; or pharmaceutically acceptable salts thereof, with the provisos that when:  
5  $R_2$  is OH,  $R_3$  is OH,  $R_4$  is  $CH_2OH$ , and  $R_6$  is xylopyranosyl,  $R_1$  is not H;  
 $R_4$  is  $CH_2OH$  and  $R_3$  is O-alkanoyl  $R_2$  is not O-acetyl; .  
 $R_4$  is  $CH_2OH$  and  $R_2$  is O-alkenoyl  $R_3$  is not hydroxyl; and  
 $R_4$  is  $CH_2OH$  and  $R_3$  is hydroxyl then  $R_2$  is not hydroxyl..

2. A compound as claimed in claim 1 wherein  $R_2$  is hydrogen, O-benzoyl, O-tigloyl or

10



wherein  $R_5$  and  $R_7$  are selected from hydrogen, tigloyl, benzoyl or benzoyl alkyl substituted alkanoyl.

3. A compound as claimed in claim 1 wherein  $R_3$  is selected from O-acetyl, O-benzoyl, O-isobutyryl or O-tigloyl.

15 4. A compound as claimed in claim 1 wherein  $R_4$  is selected from - $CH_2OH$ , O-acetyl or hydroxyl.

5. A compound as claimed in claim 1 wherein  $R_2$  is arabino pyranosyl, 3-(3-benzoyl-2-methylbutanoyl)-4-benzoyl- $\alpha$ -L-arabinopyranosyl, O-benzoyl, O-dibenzoyl, O-tigloyl, 3,4 dibenzoyl  $\alpha$ -L-arabinopyranosyl, 3-(3-benzoyl-2-methylbutyryl-4-tigloyl- $\alpha$ -L-arabinopyranosyl, 3-tigloyl-4-(3-benzoyl-2-methylbutyryl)- $\alpha$ -L-arabinopyranosyl, 3-(3-benzoyl-2 methyl butanoyl-4-benzoyl- $\alpha$ -L-arabinopyranosyl or 3-(3-benzoyl-2 methylbutyryl)-4-benzoyl- $\alpha$ -L-arabinopyranosyl.

20 6. A compound as claimed in claim 1 wherein  $R_6$  is methyl.

25 7. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21-O-[3-(3-benzoyl-2-methylbutanoyl)-4-benzoyl- $\alpha$ -L-

arabinopyranosyl]-22-O-acetyl barringtogenol C;

8. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21-O-benzoyl barringtogenol C;

9. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21-O-benzoyl-28-O-acetyl barringtogenol C;

5 10. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21-O-benzoyl-22-O-isobutyryl barringtogenol C;

11. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-methylglucuronopyranosyl-21,22-O-dibenzoyl barringtogenol C;

10 12. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21, 22-O-dibenzoyl barringtogenol C;

13. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-methylglucuronopyranosyl-21-O-benzoyl-22-O-tigloyl barringtogenol C;

14. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21-O-benzoyl-22-O-tigloyl barringtogenol C;

15 15. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-methylglucuronopyranosyl-21,22-O-tigloyl barringtogenol C;

16. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]-D-glucuronopyranosyl-21,22-O-tigloyl barringtogenol C;

20 17. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-22-O-benzoyl barringtogenol C;

18. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21-O-[3,4-dibenzoyl- $\alpha$ -L-arabinopyranosyl]-22-O-acetyl barringtogenol C;

25 19. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21-O-[3,4-dibenzoyl- $\alpha$ -L-arabinopyranosyl]-28-O-acetyl barringtogenol C;

20. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21-O-[3-(3-benzoyl-2-methylbutyryl)-4-tigloyl- $\alpha$ -L-

30 arabinopyranosyl]-22-O-acetyl barringtogenol C;

21. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21-O-[3-tigloyl-4-(3-benzoyl-2-methylbutyryl)- $\alpha$ -L-

arabinopyranosyl]-22-O-acetyl barringtogenol C;

22. 3-O- $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)- $\beta$ -D-glucuronopyranosyl-21-O-[3-(3-benzoyl-2-methylbutyryl)-4-benzoyl- $\alpha$ -L-arabinopyranosyl]-22-O-acetyl barringtogenol C.

5 23. 3-O- $\beta$ -D-xylopyranosyl(1 $\rightarrow$ 3)-[ $\beta$ -D-galactopyranosyl(1 $\rightarrow$ 2)]- $\beta$ -D-glucuronopyranosyl-21-O-[3-(3-benzoyl-2-methylbutyryl)-4-benzoyl- $\alpha$ -L-arabinopyranosyl]-28-O-acetyl barringtogenol C.

24. A pharmaceutical composition for treatment and/or control of pain comprising a therapeutically effective amount of a compound of any one

10 of claims 1 to 23 and a pharmaceutically acceptable carrier.

25. A pharmaceutical composition as claimed in claim 24 wherein the carrier is a pharmaceutically acceptable excipient.

26. A method of treating and/or controlling pain which includes the step of administering to a subject in need of such treatment at least one

15 compound as claimed in any one of claims 1 to 23.